Condition: Suvorexant · Placebo · Opioid Use Disorder · Sponsor: Johns Hopkins University
This is a 4-week, randomized-controlled trial of suvorexant vs placebo in persons with opioid use disorder who have recent fentanyl exposure. Participants will first undergo a 5-day residential phase wherein participants are stabilized on sublingual buprenorphine/naloxone, followed by a 3-week outpatient phase wherein participants are maintained on sublingual buprenorphine/naloxone and transitioned to extended-release buprenorphine).
This description comes directly from the study's public registry record.
Andrew S Huhn, Ph.D. · 410-550-1971 · ahuhn1@jhu.edu
Kelly E Dunn, Ph.D. · 410-550-2254 · kdunn9@jhmi.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins Bayview Medical Center | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05145764